|
[1]
|
Frequency and Factors Associated With Adverse Events Among Multi-Drug Resistant Tuberculosis Patients in Pakistan: A Retrospective Study
Frontiers in Medicine,
2022
DOI:10.3389/fmed.2021.790718
|
|
|
|
|
[2]
|
Assessment of Adverse Drug Events, Their Risk Factors, and Management Among Patients Treated for Multidrug-Resistant TB: A Prospective Cohort Study From Pakistan
Frontiers in Pharmacology,
2022
DOI:10.3389/fphar.2022.876955
|
|
|
|
|
[3]
|
Frequency and Management of Adverse Drug Reactions Among Drug-Resistant Tuberculosis Patients: Analysis From a Prospective Study
Frontiers in Pharmacology,
2022
DOI:10.3389/fphar.2022.883483
|
|
|
|
|
[4]
|
Incidence and predictors of major adverse drug events among drug-resistant tuberculosis patients on second-line anti-tuberculosis treatment in Amhara regional state public hospitals; Ethiopia: a retrospective cohort study
BMC Infectious Diseases,
2019
DOI:10.1186/s12879-019-3919-1
|
|
|
|
|
[5]
|
Risk Factors of Gout in MDR-TB Patients in Eritrea: A Case-Control Study
Tuberculosis Research and Treatment,
2019
DOI:10.1155/2019/9429213
|
|
|
|
|
[6]
|
Nephrotoxicity and ototoxic symptoms of injectable second-line anti-tubercular drugs among patients treated for MDR-TB in Ethiopia: a retrospective cohort study
BMC Pharmacology and Toxicology,
2019
DOI:10.1186/s40360-019-0313-y
|
|
|
|